NeOnc reports Phase 1 dose-escalation results for NEO212; RP2D set at 610 mg

NEONC TECHNOLOGIES HOLDINGS, INC.

MTD reached at 810 mg (Cohort 5) with second DLT; dose escalation halted.
Recommended Phase 2 Dose (RP2D) set at 610 mg; Phase 2a metastasis start at 400 mg.
Early efficacy signals: partial response in recurrent GBM (~60% tumor reduction after 21 cycles) and stable disease in brain metastasis.
No clinically meaningful myelosuppression; 39x lower AIC vs TMZ indicating lower toxicity.
Type B FDA meeting to be requested for accelerated approval pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.